Literature DB >> 34799557

COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types.

Benjamin J Schmiedel1, Job Rocha1,2, Cristian Gonzalez-Colin1,2, Sourya Bhattacharyya1, Ariel Madrigal1, Christian H Ottensmeier1,3, Ferhat Ay1,4, Vivek Chandra1, Pandurangan Vijayanand5,6,7.   

Abstract

Common genetic polymorphisms associated with COVID-19 illness can be utilized for discovering molecular pathways and cell types driving disease pathogenesis. Given the importance of immune cells in the pathogenesis of COVID-19 illness, here we assessed the effects of COVID-19-risk variants on gene expression in a wide range of immune cell types. Transcriptome-wide association study and colocalization analysis revealed putative causal genes and the specific immune cell types where gene expression is most influenced by COVID-19-risk variants. Notable examples include OAS1 in non-classical monocytes, DTX1 in B cells, IL10RB in NK cells, CXCR6 in follicular helper T cells, CCR9 in regulatory T cells and ARL17A in TH2 cells. By analysis of transposase accessible chromatin and H3K27ac-based chromatin-interaction maps of immune cell types, we prioritized potentially functional COVID-19-risk variants. Our study highlights the potential of COVID-19 genetic risk variants to impact the function of diverse immune cell types and influence severe disease manifestations.
© 2021. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34799557      PMCID: PMC8604964          DOI: 10.1038/s41467-021-26888-3

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


Introduction

The clinical presentation of SARS-CoV-2 infection in humans can range from very mild or no symptoms to severe respiratory failure[1]. Although hyperactivation of various cellular components of the immune system has been observed in patients with severe COVID-19 illness[2,3], the host genetic factors that determine susceptibility to severe COVID-19 illness are not well understood. Genome-wide association studies (GWAS) addressing this question have identified a number of genetic variants associated with COVID-19 susceptibility and severity[4-8]. Several target genes associated with these COVID-19 risk variants were defined based on their proximity to the risk loci[4-8], although this approach does not accurately prioritize causal genes[9]. To determine putative causal genes, a recent COVID-19 GWAS additionally conducted Mendelian randomization (MR) and transcriptome-wide association study (TWAS), utilizing information from expression quantitative trait loci (eQTLs) datasets in lung tissues and whole blood (GTEx project), and identified significant associations with the expression of seven genes (IFNAR2, TYK2 from MR analysis, and CCR2, CCR3, CXCR6, MAT2B, OAS3 from TWAS analysis)[7]. Because the effects of common genetic variants on gene expression are highly cell-type-specific[10], utilizing eQTL datasets from tissue samples with substantial cellular heterogeneity, like whole blood, is likely to miss associations that are cell-type-specific, and also fail to pin-point the precise cell types where the effects of COVID-19-risk variants are most prominent. Furthermore, the impact of COVID-19-risk variants on gene expression in cell types that play a key role in COVID-19 pathogenesis, such as immune cell types, has not been fully explored. The DICE database of immune cell gene expression, epigenomics, and expression quantitative trait loci (eQTLs) (http://dice-database.org) was established to precisely address these questions as well as to help narrow down functional variants in dense haploblocks linked to disease susceptibility[10,11]. Here, we utilize eQTLs (DICE database) and chromatin accessibility profiles of 13 different immune cell types and two cell types in activated conditions, as well as 3D cis-interactome maps to prioritize target genes and cell types where expression of genes is most affected by genetic variants linked to COVID-19 severity and susceptibility.

Results

Target genes associated with COVID-19 risk variants in immune cell types

We utilized publicly available data from meta-analyses of GWAS for three COVID-19 phenotypes: (A) critical COVID-19 illness, (B) moderate to severe COVID-19 illness requiring hospitalization, and (C) reported SARS-CoV-2 infection (COVID-19 Host Genetics Initiative, release 5 from January 18, 2021[4]; GWAS association P value <5 × 10−8; Supplementary Fig. 1a). These meta-analyses reported 19 independent loci that were significantly associated with COVID-19 disease severity (A or B) or susceptibility (C)[12]. To predict cell types that are likely to be major contributors to the genetic risk of COVID-19, we first assessed enrichment of COVID-19-risk variants in cis-regulatory regions from a wide range of cell types and tissues using GARFIELD[13] software. As expected, COVID-19-risk variants showed significant enrichment in chromatin accessibility regions (ATAC-seq and DNase-seq peaks) from blood cells and immune cell types, but little or no enrichment in other tissues and cell types (Supplementary Fig. 1b and Supplementary Data 1). To determine potential target genes and immune cell types where the effects of COVID-19-risk variants are most prominent, we first assessed the overlap of COVID-19-risk variants with DICE eQTLs from 13 different immune cell types and two cell types in activated conditions. We found that variants in 10 COVID-19-risk loci were significantly associated in cis with the expression of 37 genes (called as eGenes) in immune cell types (Table 1, Supplementary Data 2, and Supplementary Fig. 2). However, due to the high enrichment of GWAS loci in eQTL regions, this simple overlap approach can lead to false associations[9]. Therefore, we utilized two complementary statistical frameworks, colocalization analysis[14,15], and TWAS[9,16,17], to prioritize putative casual genes in immune cell types that are linked to COVID-19 severity or susceptibility. We performed colocalization analysis using the COLOC framework[14,15] to determine the posterior probability of a variant to be significantly associated with both COVID-19 risk and gene expression (eQTL) (see Methods). GWAS variants in 5 independent COVID-19-risk loci showed the high posterior probability of colocalization (PP4 > 0.5 and PP4/PP3 ratio ≥5)[15,18-21] with eQTLs associated with the expression of 9 eGenes (Table 1, Fig. 1a, Supplementary Fig. 3a, b, and Supplementary Data 3). Notably, a large fraction of these eGenes showed prominent effects in specific immune cell types (Fig. 1b). Next, we employed PrediXcan framework[17] to build models, which can predict gene expression in immune cell types using DICE-eQTL dataset. Single-tissue (S-PrediXcan[17]) and integrated (S-MulTiXcan[16]) TWAS using these models showed that the expression of nine genes in four independent loci was significantly associated with COVID-19 severity or susceptibility (Table 1, Fig. 1c, d, Supplementary Fig. 3c, d, and Supplementary Data 4 and 5). For many genes (e.g., OAS1, IL10RB, DTX1, DONSON, CCR9, FYCO1, ACBD4, ARL17A, LRRC37A2, NSF, NXPE3), our TWAS and colocalization analysis using immune cell eQTLs (DICE dataset) provide the first evidence that their expression in specific immune cell types is likely to be causally linked to COVID-19 severity or susceptibility (Table 1).
Table 1

Prioritization of target genes associated with COVID-19-risk GWAS variants in immune cell types.

Location of COVID-19 risk locusCount of significant GWAS SNPs in locusMost significant GWAS SNP (rsID)eGenes associated with COVID-19 GWAS variants identified by different methods in DICE dataseteGenes identified by Pairo-Castineira et al.[7]Suggested COVID-19 phenotype
Overlap of COVID-19-risk GWAS variants with DICE eQTLsColocalization analysis (COLOC)TWAS analysis (S-PrediXcan)TWAS analysis (S-MulTiXcan)
chr1: 155,105,882–155,173,5274rs4971066RP11-307C12.11, THBS3, GBAP1, MTX1P1, ASH1LHospitalization, infection risk
chr3: 45,637,109–46,573,675630rs35081325CXCR6, FYCO1, CCR1, CCR2CXCR6, FYCO1CCR9, CXCR6CCR9, CXCR6CXCR6, CCR3, CCR2Critical illness, hospitalization, infection risk
chr3: 101,274,911–101,535,347133rs10936744FAM172BP, ZBTB11-AS1, NXPE3NXPE3Infection risk
chr3: 197,127,0091rs9816840Critical illness
chr6: 31,120,729–31,121,9585rs111837807TCF19Critical illness, hospitalization
chr6: 33,055,3551rs9501257HLA-DMA, RPL32P1Critical illness
chr6: 41,502,6831rs1886814Hospitalization
chr7: 54,647,8941rs622568Critical illness, hospitalization
chr7: 107,607,9021rs2237698Critical illness
chr8: 125,336,5641rs72711165Hospitalization
chr9: 136,132,012–136,296,53073rs8176719Hospitalization, infection risk
chr12: 103,014,7571rs10860891Critical illness, hospitalization
chr12: 113,350,796–113,425,679133rs10735079OAS1, OAS3, DTX1OAS1, OAS3, DTX1OAS1OAS1OAS3Critical illness, hospitalization, infection risk
chr15: 100,774,0211rs143434383Infection risk
chr17: 43,705,356–44,863,1331110rs1819040ACBD4, HEXIM1, SPATA32, LRRC37A4P, DND1P1, CRHR1-IT1, RP11-669E14.6, KANSL1, KANSL1-AS1, ARL17B, LRRC37A2, ARL17A, NSF, WNT3NSFACBD4,LRRC37A2, ARL17ALRRC37A2Hospitalization
chr17:47,868,921–47,940,6666rs77534576ACSF2Critical illness
chr19:4,684,642–4,724,73411rs2109069Critical illness, hospitalization, infection risk
chr19:10,427,721–10,477,0674rs74956615PDE4A, CTC-215O4.4Critical illness, hospitalization
chr21:34,589,811–34,634,87864rs13050728IFNAR2, IL10RBIFNAR2, IL10RBIFNAR2, IL10RB, DONSONIFNAR2, IL10RBIFNAR2Critical illness, hospitalization, infection risk
Fig. 1

Prioritization of genes and immune cell types linked to COVID-19-risk variants.

a Colocalization analysis. Left panel, a ternary plot showing the posterior probabilities of various configurations from COLOC analysis for each gene–cell-type pairs (PP0 = variant with no association, PP1 = variant with association only with COVID-19 phenotype, PP2 = variant with association only with gene expression (PP0 + PP1 + PP2 = underpowered signals), PP3 = independent association of variants with COVID-19 phenotype and gene expression, PP4 = colocalized variant, where a single causal SNPs is associated with both COVID-19 phenotype and gene expression; see “Methods”). Genes with a high probability of colocalized signals (PP4 > 0.5 and PP4/PP3 ratio ≥5, highlighted in the yellow shade and shown in the right panel) in a specific immune cell type represent putative causal genes linked to COVID-19 risk. Right panel, genes, and immune cell types influenced by variants associated with COVID-19 phenotypes (combined results of all three COVID-19 phenotypes from GWAS meta-analyses; see “Methods”). For eGenes with colocalized signals (rows), the posterior probabilities of colocalized GWAS and eQTL signals (PP4) is shown for different immune cell types (columns). b Fractions of COVID-19-risk eGenes with colocalized signals identified in varying numbers of immune cell types. c Single-tissue TWAS (S-PrediXcan[17]): gene-level Manhattan plot showing the association P value (−log10) for gene expression with COVID-19 phenotypes; results from single tissue TWAS analysis across tissues is shown (see Methods). The red horizontal line shows gene-level Bonferroni corrected genome-wide significant P value threshold (P < 1.613 × 10−6). d Z scores showing the direction of effect for the genotype-inferred expression of transcripts that encode protein-coding genes in human immune cell types. Red circles indicate genes with Bonferroni corrected genome-wide significant P value threshold (P < 1.613 × 10−6).

Prioritization of target genes associated with COVID-19-risk GWAS variants in immune cell types.

Prioritization of genes and immune cell types linked to COVID-19-risk variants.

a Colocalization analysis. Left panel, a ternary plot showing the posterior probabilities of various configurations from COLOC analysis for each gene–cell-type pairs (PP0 = variant with no association, PP1 = variant with association only with COVID-19 phenotype, PP2 = variant with association only with gene expression (PP0 + PP1 + PP2 = underpowered signals), PP3 = independent association of variants with COVID-19 phenotype and gene expression, PP4 = colocalized variant, where a single causal SNPs is associated with both COVID-19 phenotype and gene expression; see “Methods”). Genes with a high probability of colocalized signals (PP4 > 0.5 and PP4/PP3 ratio ≥5, highlighted in the yellow shade and shown in the right panel) in a specific immune cell type represent putative causal genes linked to COVID-19 risk. Right panel, genes, and immune cell types influenced by variants associated with COVID-19 phenotypes (combined results of all three COVID-19 phenotypes from GWAS meta-analyses; see “Methods”). For eGenes with colocalized signals (rows), the posterior probabilities of colocalized GWAS and eQTL signals (PP4) is shown for different immune cell types (columns). b Fractions of COVID-19-risk eGenes with colocalized signals identified in varying numbers of immune cell types. c Single-tissue TWAS (S-PrediXcan[17]): gene-level Manhattan plot showing the association P value (−log10) for gene expression with COVID-19 phenotypes; results from single tissue TWAS analysis across tissues is shown (see Methods). The red horizontal line shows gene-level Bonferroni corrected genome-wide significant P value threshold (P < 1.613 × 10−6). d Z scores showing the direction of effect for the genotype-inferred expression of transcripts that encode protein-coding genes in human immune cell types. Red circles indicate genes with Bonferroni corrected genome-wide significant P value threshold (P < 1.613 × 10−6).

The COVID-19 risk allele is associated with reduced OAS1 expression non-classical monocytes

Potential defects in the type 1 interferon signaling pathway have been reported in patients with severe COVID-19 illness[22-25]. Here, we found that colocalized severe COVID-19-risk variants in chromosome 21 were associated with reduced expression of the gene encoding interferon receptor 2 (IFNAR2) in 12 of the 13 immune cell types analyzed (Fig. 2a). TWAS also showed a significant association of COVID-19 severity with reduced expression of IFNAR2 in multiple immune cell types, thus supporting a role for impaired interferon signaling in immune cells in the pathogenesis of severe COVID-19 illness (Fig. 1c, d). In addition, we found that colocalized severe COVID-19-risk variants in another independent locus (chromosome 12) were also associated with reduced expression of two interferon-inducible genes (OAS1 and OAS3) (Fig. 2a–e). OAS1 and OAS3 encode for the oligoadenylate synthase family of proteins that degrade viral RNA and activate antiviral responses[26]. OAS1 showed a peak COVID-19-risk eQTL (rs4767032, adj. association P value = 1.05 × 10−6) specifically in patrolling non-classical monocytes (NCM) (Fig. 2a), whereas OAS3 showed prominent eQTLs in T-cell subsets (Fig. 2a), highlighting cell type-restricted effects of COVID-19-risk variants. In NCM, TWAS confirmed that reduced expression of OAS1 is associated with the severity of COVID-19 illness (Fig. 1c, d and Supplementary Data 4 and 5). NCM plays a protective role in viral infections[27], and they have been shown to activate T cells and NK cells as well as produce cytokines that can promote TH1 immune responses[28-31]. Interestingly, immuno-profiling studies in COVID-19 patients have reported a dramatic reduction in the frequency of NCM in COVID-19 illness[32,33]. Thus, genetic variants that reduce OAS1 expression are likely to impair the degradation of SARS-CoV-2 RNA and antiviral responses triggered by NCM, which may contribute to the pathogenesis of severe COVID-19 illness.
Fig. 2

COVID-19-risk variants affect genes in the IFN response pathway.

a Mean expression levels (TPM) of selected severe COVID-19-risk-associated eGenes (all with GWAS association P value <5 × 10−8) identified by colocalization analysis in the indicated cell types from subjects (n = 91) categorized based on the genotype at the indicated GWAS cis-eQTL; each symbol represents an individual subject; adj. association P value *P < 0.05, **P < 0.001, and ***P < 0.00001. The boxplots show the 25th percentile, median, and 75th percentile, with the whiskers indicating the minimum and maximum values. b Plot shows GWAS association P value for COVID-19-risk variants in the indicated locus; the colocalized variants for OAS1 in non-classical monocytes (rs10774671, orange circle), OAS3 in naive CD4+ T cells (rs1293765, blue circle) and naive CD8+ T cells (rs10774679, pink circle) are highlighted. c Locus compare plots[63] for OAS1 in non-classical monocytes (left panel), OAS3 in naive CD4+ T cells (middle panel), and in naive CD8+ T cells (right panel). Each variant is plotted to represent its −log10 COVID-19 GWAS association P value (x axis) and the −log10 association P value for cis-eQTLs associated with expression of the indicated gene (y axis). The colors denote the strength of linkage disequilibrium (LD) with the indicated lead SNP from the colocalization analysis (purple diamond). d Top panel, WashU Epigenome Browser tracks for the OAS1 locus, COVID-19-risk-associated GWAS variants (based on respective GWAS meta-analyses, see Supplementary Fig. 1a), adj. association P values for cis-eQTLs associated with expression of OAS1 in classical monocytes and non-classical monocytes, recombination rate tracks[64,65], ATAC-seq tracks, H3K27ac ChIP-seq tracks, and H3K27ac HiChIP-based chromatin-interactions in classical monocytes and non-classical monocytes (NCM). Bottom panel, OAS1 eQTLs that overlap the NCM-specific cis-regulatory region (chr12:113,362,201-113,365,200; see “Methods”), of which three SNPs at the peak of the transposase-accessible region are predicted to disrupt three distinct binding motifs of RXRα (see Supplementary Data 7) and overlap RXRα binding sites in ENCODE chromatin immunoprecipitation sequencing (ChIP-seq) data of liver tissue and liver cell lines[36]. e Top panel, WashU Epigenome Browser tracks for the OAS3 locus, COVID-19-risk-associated GWAS variants (based on respective GWAS meta-analyses, see Supplementary Fig. 1a), adj. association P values for cis-eQTLs associated with expression of OAS3 in naive CD4+ T cells and naive CD8+ T cells, recombination rate tracks[64,65], ATAC-seq tracks, H3K27ac ChIP-seq tracks, and H3K27ac HiChIP-based chromatin-interactions in naive CD4+ T cells and naive CD8+ T cells. Bottom panel, OAS3 eQTLs that overlap OAS2 promoter region (chr12:113,415,001-113,420,000; see “Methods”), of which one eQTL (rs1298962) is predicted to disrupt the binding of GATA3 (see Supplementary Data 7) and overlaps a GATA3-binding site identified in human thymocytes[39].

COVID-19-risk variants affect genes in the IFN response pathway.

a Mean expression levels (TPM) of selected severe COVID-19-risk-associated eGenes (all with GWAS association P value <5 × 10−8) identified by colocalization analysis in the indicated cell types from subjects (n = 91) categorized based on the genotype at the indicated GWAS cis-eQTL; each symbol represents an individual subject; adj. association P value *P < 0.05, **P < 0.001, and ***P < 0.00001. The boxplots show the 25th percentile, median, and 75th percentile, with the whiskers indicating the minimum and maximum values. b Plot shows GWAS association P value for COVID-19-risk variants in the indicated locus; the colocalized variants for OAS1 in non-classical monocytes (rs10774671, orange circle), OAS3 in naive CD4+ T cells (rs1293765, blue circle) and naive CD8+ T cells (rs10774679, pink circle) are highlighted. c Locus compare plots[63] for OAS1 in non-classical monocytes (left panel), OAS3 in naive CD4+ T cells (middle panel), and in naive CD8+ T cells (right panel). Each variant is plotted to represent its −log10 COVID-19 GWAS association P value (x axis) and the −log10 association P value for cis-eQTLs associated with expression of the indicated gene (y axis). The colors denote the strength of linkage disequilibrium (LD) with the indicated lead SNP from the colocalization analysis (purple diamond). d Top panel, WashU Epigenome Browser tracks for the OAS1 locus, COVID-19-risk-associated GWAS variants (based on respective GWAS meta-analyses, see Supplementary Fig. 1a), adj. association P values for cis-eQTLs associated with expression of OAS1 in classical monocytes and non-classical monocytes, recombination rate tracks[64,65], ATAC-seq tracks, H3K27ac ChIP-seq tracks, and H3K27ac HiChIP-based chromatin-interactions in classical monocytes and non-classical monocytes (NCM). Bottom panel, OAS1 eQTLs that overlap the NCM-specific cis-regulatory region (chr12:113,362,201-113,365,200; see “Methods”), of which three SNPs at the peak of the transposase-accessible region are predicted to disrupt three distinct binding motifs of RXRα (see Supplementary Data 7) and overlap RXRα binding sites in ENCODE chromatin immunoprecipitation sequencing (ChIP-seq) data of liver tissue and liver cell lines[36]. e Top panel, WashU Epigenome Browser tracks for the OAS3 locus, COVID-19-risk-associated GWAS variants (based on respective GWAS meta-analyses, see Supplementary Fig. 1a), adj. association P values for cis-eQTLs associated with expression of OAS3 in naive CD4+ T cells and naive CD8+ T cells, recombination rate tracks[64,65], ATAC-seq tracks, H3K27ac ChIP-seq tracks, and H3K27ac HiChIP-based chromatin-interactions in naive CD4+ T cells and naive CD8+ T cells. Bottom panel, OAS3 eQTLs that overlap OAS2 promoter region (chr12:113,415,001-113,420,000; see “Methods”), of which one eQTL (rs1298962) is predicted to disrupt the binding of GATA3 (see Supplementary Data 7) and overlaps a GATA3-binding site identified in human thymocytes[39]. To explore the molecular mechanisms that explain cell-specific effects of COVID-19-risk variants in the OAS1 loci, we performed (assay for transposase-accessible chromatin) ATAC-seq analysis of the 13 DICE immune cell types and two activation conditions, and also generated H3K27ac ChIP-seq as well as HiChIP-based chromatin-interaction maps in NCM (see “Methods”). Although the OAS1 promoter did not directly overlap COVID-19-risk variants, we found several fine-mapped[34,35] COVID-19-risk variants, associated with OAS1 expression (eQTLs) (Supplementary Data 6), directly overlapped an intergenic transposase-accessible and H3K27ac-enriched peak region, located 20 kb away from OAS1 promoter (Fig. 2d). This potential cis-regulatory region directly interacted with OAS1 promoter in NCM (Fig. 2d), which suggested that perturbation of its activity by OAS1 eQTLs is likely to explain their cell-type-specific effects. The OAS1 eQTLs in the NCM-specific H3K27ac peak region were predicted to disrupt the binding sites of several transcription factors (Supplementary Data 7). Most notable was the perturbation of three independent binding sites for retinoid X receptor alpha (RXRα), which has also been shown to bind to this DNA region (ENCODE Transcription factor ChIP-seq in liver tissue and liver cell lines[36]) (Fig. 2d, bottom panel). Given the recognized role of RXRα in regulating gene expression in monocytes[37], we speculate that perturbation of RXRα binding to the NCM-specific cis-regulatory region could result in reduced OAS1 expression specifically in NCM.

Cell type-restricted effects of COVID-19-risk variants

The COVID-19-risk variants in the OAS1/OAS3/OAS2 locus were also associated with reduced expression of OAS3 in certain T cell subsets but not in monocytes, NK cells, or B cells (Fig. 2a). Accordingly, in naive T cells but not monocytes, the OAS3 promoter interacted with the promoter of the neighboring gene OAS2 that harbors OAS3 eQTLs (peak eQTL rs1298962, adj. association P value = 3.75 × 10−5) (Fig. 2e), suggesting that perturbation of this T cell-specific cis-regulatory interaction is likely to explain the cell-specific effects of OAS3 eQTLs. This notion is supported by recent reports showing that promoters can interact with neighboring gene promoters and regulate their expression[11,38]. Notably, the OAS3 eQTL (rs1298962) was also identified as a putative causal variant by fine-mapping[34,35] (Supplementary Data 6) and predicted to disrupt the binding site of GATA3, a T-cell transcription factor that has previously been shown to bind to the neighboring OAS2 promoter region in human thymocytes[39], suggesting a potentially important role in regulating OAS3 expression (Fig. 2e, bottom panel and Supplementary Data 7). Of note, we also identified a canonical GATA motif 10 nucleotides upstream of rs1298962 (Fig. 2e, bottom panel), which led us to hypothesize that this variant may modulate the binding affinity of GATA3 either by perturbation of a submaximal recognition motif that affects enhancer syntax (“suboptimization”) or by motif independent mechanisms[40-42]. Interestingly, we found that another colocalized severe COVID-19-risk variant (rs2010604, adj. association P value = 4.50 × 10−2) in the OAS1/OAS3/OAS2 locus influenced the expression of a neighboring gene (DTX1) specifically in naive B cells (Fig. 3a–c). Active chromatin-interaction maps in naive B cells showed that a cis-regulatory region near the eQTL (rs2010604) indirectly interacted with the promoter of DTX1, located >80 kb away, and likely modulates its transcriptional activity (Fig. 3d). DTX1, encodes for a ubiquitin ligase Deltex1 that regulates NOTCH activity in B cells[43]. Deltex1 has also been shown to promote anergy, a functionally hypo-responsive state, in T cells[44]; if Deltex1 has similar functions in B cells, then genetic modulation of DTX1 levels may have a profound impact on the function of B cells in COVID-19 illness. In summary, our search for target genes in the severe COVID-19-risk loci in chromosome 12 revealed three putative causal eGenes that display prominent cell-type-restricted effects—OAS1 in NCM, OAS3 in T-cell subsets, and DTX1 in B cells.
Fig. 3

Cell type-restricted effects of COVID-19-risk variants.

a Mean expression levels (TPM) of severe COVID-19-risk-associated GWAS eGenes DTX1 and IL10RB in the indicated cell types from subjects (n = 91) categorized based on the genotype at the indicated GWAS cis-eQTL; each symbol represents an individual subject; adj. association P value *P < 0.05, **P < 0.001, and ***P < 0.00001. The boxplots show the 25th percentile, median, and 75th percentile, with the whiskers indicating the minimum and maximum values. b Plot shows GWAS association P value for COVID-19-risk variants in the indicated locus; the colocalized variant for DTX1 in naive B cells (rs2010604, green circle) is highlighted. c Locus compares plots[63] for DTX1 in naive B cells. Each variant is plotted to represent its -log10 COVID-19 GWAS association P value (x axis) and the −log10 association P value for cis-eQTLs associated with the expression of DTX1 (y axis). The colors denote the strength of linkage disequilibrium (LD) with the indicated lead SNP from the colocalization analysis (purple diamond). d WashU Epigenome Browser tracks for the DTX1 locus, COVID-19-risk-associated GWAS variants (based on respective GWAS meta-analyses, see Supplementary Fig. 1a), adj. association P values for cis-eQTLs associated with expression of DTX1 in naive B cells, recombination rate tracks[64,65], ATAC-seq tracks, H3K27ac ChIP-seq tracks, and H3K27ac HiChIP-based chromatin-interactions in naive B cells. e Plot shows GWAS association P value for COVID-19-risk variants in the indicated locus; the colocalized variants for IL10RB in NK cells (rs12053666, yellow circle), and IFNAR2 in naive CD4+ T cells (rs12482556, blue circle) and naive CD8+ T cells (rs2252639, pink circle) are highlighted. f Locus compares plots[63] for IL10RB in NK cells. Each variant is plotted to represent its −log10 COVID-19 GWAS P value (x axis) and the −log10 association P value for cis-eQTLs associated with the expression of IL10RB (y axis). The colors denote the strength of linkage disequilibrium (LD) with the indicated lead SNP from the colocalization analysis (purple diamond). g WashU Epigenome Browser tracks for the IL10RB locus, COVID-19-risk-associated GWAS variants (based on respective GWAS meta-analyses, see Supplementary Fig. 1a), adj. association P values for cis-eQTLs associated with expression of IL10RB in NK cells, recombination rate tracks[64,65], ATAC-seq tracks, H3K27ac ChIP-seq tracks, and H3K27ac HiChIP-based chromatin-interactions in NK cells.

Cell type-restricted effects of COVID-19-risk variants.

a Mean expression levels (TPM) of severe COVID-19-risk-associated GWAS eGenes DTX1 and IL10RB in the indicated cell types from subjects (n = 91) categorized based on the genotype at the indicated GWAS cis-eQTL; each symbol represents an individual subject; adj. association P value *P < 0.05, **P < 0.001, and ***P < 0.00001. The boxplots show the 25th percentile, median, and 75th percentile, with the whiskers indicating the minimum and maximum values. b Plot shows GWAS association P value for COVID-19-risk variants in the indicated locus; the colocalized variant for DTX1 in naive B cells (rs2010604, green circle) is highlighted. c Locus compares plots[63] for DTX1 in naive B cells. Each variant is plotted to represent its -log10 COVID-19 GWAS association P value (x axis) and the −log10 association P value for cis-eQTLs associated with the expression of DTX1 (y axis). The colors denote the strength of linkage disequilibrium (LD) with the indicated lead SNP from the colocalization analysis (purple diamond). d WashU Epigenome Browser tracks for the DTX1 locus, COVID-19-risk-associated GWAS variants (based on respective GWAS meta-analyses, see Supplementary Fig. 1a), adj. association P values for cis-eQTLs associated with expression of DTX1 in naive B cells, recombination rate tracks[64,65], ATAC-seq tracks, H3K27ac ChIP-seq tracks, and H3K27ac HiChIP-based chromatin-interactions in naive B cells. e Plot shows GWAS association P value for COVID-19-risk variants in the indicated locus; the colocalized variants for IL10RB in NK cells (rs12053666, yellow circle), and IFNAR2 in naive CD4+ T cells (rs12482556, blue circle) and naive CD8+ T cells (rs2252639, pink circle) are highlighted. f Locus compares plots[63] for IL10RB in NK cells. Each variant is plotted to represent its −log10 COVID-19 GWAS P value (x axis) and the −log10 association P value for cis-eQTLs associated with the expression of IL10RB (y axis). The colors denote the strength of linkage disequilibrium (LD) with the indicated lead SNP from the colocalization analysis (purple diamond). g WashU Epigenome Browser tracks for the IL10RB locus, COVID-19-risk-associated GWAS variants (based on respective GWAS meta-analyses, see Supplementary Fig. 1a), adj. association P values for cis-eQTLs associated with expression of IL10RB in NK cells, recombination rate tracks[64,65], ATAC-seq tracks, H3K27ac ChIP-seq tracks, and H3K27ac HiChIP-based chromatin-interactions in NK cells.

The COVID-19 risk allele is associated with increased IL10RB expression in multiple immune cell types

We found that severe COVID-19-risk variants in the IFNAR2 locus (chromosome 21) were colocalized with eQTLs linked to increased expression of the neighboring gene IL10RB in NK cells and T-cell subsets (rs12482556, adj. association P value = 4.93 × 10−5 in NK cells) (Fig. 3a, e, f). TWAS also confirmed the association of COVID-19 severity with increased expression of IL10RB (Fig. 1c, d). H3K27ac HiChIP-based chromatin-interaction maps in NK cells showed that multiple cis-regulatory regions, including the IFNAR2 promoter, harbor COVID-19-risk eQTLs and directly or indirectly interact with the IL10RB promoter and potentially influence its expression (Fig. 3g). IL10RB encodes for IL-10 receptor beta, and given the immunomodulatory role of IL-10[45,46], it is likely that the higher expression on the IL10RB in NK cells and T cells may enhance their responsiveness to IL-10. Thus, our findings point to a potentially important role for IL-10 signaling and NK cells in influencing the severity of COVID-19 illness. Genetic variants in the 3p21.31 locus have been linked to the severity of COVID-19 illness by multiple GWAS studies[4-7,12]. The severe COVID-19-risk variants in the 3p21.31 locus contains 17 known protein-coding genes (Fig. 1c), including SLC6A20, LZTFL1, CCR9, FYCO1, CXCR6, XCR1, CCR1, CCR3, CCR2, and CCR5. A previous TWAS using whole blood and lung eQTL datasets reported a significant association between COVID-19 severity and expression of chemokine receptor encoding genes CCR2, CCR3, and CXCR6 in lung tissue[7]. We found that variants in the 3p21.31 locus colocalized with distinct eQTLs linked to CXCR6 and FYCO1 expression in TFH cells and stimulated naive T cells, respectively (Fig. 4a, c). In naive regulatory T cells, TWAS found a significant association between COVID-19 severity and CCR9, which encodes for the gut-homing chemokine receptor CCR9[47] (Fig. 1c, d and Supplementary Data 4 and 5). In other T-cell subsets like TFH, TH2, and TH1/17 cells, TWAS also revealed associations between expression of genes in chromosome 17 (ACBD4, ARL17A, and LRRC37A2) and COVID-19 disease severity (Fig. 4b, c). As expected, we found the expression of these genes in the corresponding T-cell subset was significantly associated with distinct COVID-19-risk variants in this region.
Fig. 4

COVID-19-risk-associated genes prioritized by colocalization analysis and TWAS.

a WashU Epigenome Browser tracks for the gene locus on chromosome 3 harboring the genes FYCO1, CXCR6, and CCR9, COVID-19-risk-associated GWAS variants (based on respective GWAS meta-analyses, see Supplementary Fig. 1a), adj. association P values for cis-eQTLs associated with expression of the indicated genes in various immune cell types and conditions. b WashU Epigenome Browser tracks for the gene locus on chromosome 17 harboring the genes ACBD4, LRRC37A2, and ARL17A, COVID-19-risk-associated GWAS variants (based on respective GWAS meta-analyses, see Supplementary Fig. 1a), adj. association P values for cis-eQTLs associated with expression of the indicated genes in various immune cell types and conditions. c Mean expression levels (TPM) of selected COVID-19-risk-associated GWAS eGenes (GWAS association P value <5 × 10−8), in the indicated cell types from subjects (n = 91) categorized based on the genotype at the indicated GWAS cis-eQTL; each symbol represents an individual subject; adj. association P value *P < 0.05, **P < 0.001, and ***P < 0.00001. The boxplots show the 25th percentile, median, and 75th percentile, with the whiskers indicating the minimum and maximum values. Significant associations with COVID-19 GWAS variants found by colocalization (CXCR6 and FYCO1) or TWAS analysis (CCR9, CXCR6, ACBD4, ARL17A, and LRRC37A2) are highlighted for each specific immune cell type.

COVID-19-risk-associated genes prioritized by colocalization analysis and TWAS.

a WashU Epigenome Browser tracks for the gene locus on chromosome 3 harboring the genes FYCO1, CXCR6, and CCR9, COVID-19-risk-associated GWAS variants (based on respective GWAS meta-analyses, see Supplementary Fig. 1a), adj. association P values for cis-eQTLs associated with expression of the indicated genes in various immune cell types and conditions. b WashU Epigenome Browser tracks for the gene locus on chromosome 17 harboring the genes ACBD4, LRRC37A2, and ARL17A, COVID-19-risk-associated GWAS variants (based on respective GWAS meta-analyses, see Supplementary Fig. 1a), adj. association P values for cis-eQTLs associated with expression of the indicated genes in various immune cell types and conditions. c Mean expression levels (TPM) of selected COVID-19-risk-associated GWAS eGenes (GWAS association P value <5 × 10−8), in the indicated cell types from subjects (n = 91) categorized based on the genotype at the indicated GWAS cis-eQTL; each symbol represents an individual subject; adj. association P value *P < 0.05, **P < 0.001, and ***P < 0.00001. The boxplots show the 25th percentile, median, and 75th percentile, with the whiskers indicating the minimum and maximum values. Significant associations with COVID-19 GWAS variants found by colocalization (CXCR6 and FYCO1) or TWAS analysis (CCR9, CXCR6, ACBD4, ARL17A, and LRRC37A2) are highlighted for each specific immune cell type.

Discussion

Several COVID-19-risk variants show cell-type-restriction of their effects on gene expression, and thus have the potential to impact the function of diverse immune cell types and gene pathways. Our analysis of eQTLs, transposase accessible chromatin profiles, and cis-interaction maps in multiple immune cell types enabled a precise definition of the cell types and genes that drive genetic susceptibility to severe COVID-19 illness, potentially contributing to different clinical outcomes. However, COVID-19-risk variants may display stronger associations with gene expression in other immune cell types and activation conditions not examined in this work. Our study also highlights how information about common genetic polymorphisms can be used to define molecular pathways and cell types that play a role in disease pathogenesis.

Methods

Leukapheresis samples

The Institutional Review Board (IRB) of the La Jolla Institute for Allergy and Immunology (LJI; IRB protocol no. SGE-121-0714) approved the study. For the DICE study, a total of 91 healthy volunteers were recruited in the San Diego area, who provided leukapheresis samples at the San Diego Blood Bank (SDBB) after written informed consent. All study subjects self-reported ethnicity and race details, and were tested negative for hepatitis B, hepatitis C, and human immunodeficiency virus (HIV).

DICE eQTLs and re-analysis of HLA transcript levels using HLApers

Details of gene expression and eQTL analysis in 13 immune cell types and two cell types in activated conditions have been reported for the DICE project (recalculated to incorporate four previously missing RNA-seq samples; GENCODE annotation v19 (GRCh37.p13))[10]. HLA genes are highly polymorphic leading to inaccurate quantification of transcript levels from RNA-seq which hinders eQTL identification. To address this problem, we re-analyzed our RNA-seq data for all cell types using a recent method (HLApers[48]) that quantifies HLA transcript levels considering the polymorphic nature of HLA genes. Briefly, we applied the HLApers pipeline (https://github.com/genevol-usp/HLApers) for in silico HLA mapping and obtaining transcript expression as performed earlier for all remaining cell types. This pipeline generates personalized HLA index files for individual samples, which are used to estimate sample-specific HLA genotype. We applied HLApers with its default settings, aside from customizing it to support our single-end reads. We executed HLApers by using STAR as the aligner and Salmon for quantifying the transcripts. Matrix eQTL was used to obtain eQTLs from the HLApers-computed gene expression values for HLA genes. For all downstream analysis, we replaced the HLA eQTLs from the initial DICE release with this revised analysis.

COVID-19 GWAS datasets and overlap with DICE eQTLs

Genetic variants associated with COVID-19 phenotypes: (A) critical COVID-19 illness, (B) moderate to severe COVID-19 illness requiring hospitalization and (C) reported SARS-CoV-2 infection, were downloaded from the COVID-19 Host Genetics Initiative (release 5 from January 18, 2021). Genetic variants with GWAS association P value < 5 × 10−8 were utilized for downstream analysis. Linkage disequilibrium (LD) for lead COVID-19-risk variants was calculated using PLINK v1.90b3w[49] for continental “super-populations” (AFR, AMR, EAS, EUR, SAS) based on data from phase 3 of the 1000 Genomes Project[50]. SNPs in tight genetic linkage with GWAS lead SNPs (LD threshold r2 > 0.80) in any of the five super-populations were retrieved along with the SNP information (e.g., genomic location, allelic variant, allele frequencies). Utilizing this dataset, GWAS SNPs (lead SNPs and SNPs in LD) were analyzed for overlap with eQTLs in the DICE database (raw P value <0.0001, adj. association P value (FDR) < 0.05, TPM >1.0) separately for each cell type to identify COVID-19-risk variants that were associated with gene expression in immune cell types (Table 1 and Supplementary Data 2).

Colocalization analysis

To determine whether the association of GWAS variant with COVID-19 phenotypes is mediated through regulation of gene expression by the variant (eQTL), we employed colocalization analysis using the COLOC framework[14,15]. COLOC estimates the posterior probability that a GWAS variant and an eQTL in a given COVID-19-risk loci share the same causal variant. First, we extracted significant GWAS variants associated with COVID-19 phenotypes (association P value <5 × 10−8; COVID-19 Host Genetics Initiative; release 5 from January 18, 2021) and obtained GWAS summary statistics: association P values, effect size estimate (β), and standard error of β. For each eGene in immune cell types (DICE eQTL database), we extracted eQTL summary statistics: association P values, the effect size estimate (β), standard error of β, and minor allele frequency for all the variants within 1 Mb of TSS of that eGene. As suggested in a previous report[51], we excluded all variants within the MHC locus (chr6: 28,477,897–33,448,354). For each eGene, both eQTL and GWAS summary statistics were then applied to the coloc.abf routine of the COLOC package. For each immune cell type (n = 15), an independent COLOC analysis was performed using GWAS summary statistics from each COVID-19 phenotype. We used the default setting (p1 or p2 = 1 × 10−4) for the prior probability of a variant being associated with either COVID-19 phenotype (p1) or gene expression (p2). The prior probability (p12) of a variant to be associated with both COVID-19 phenotype and gene expression was determined by sensitivity analysis, as recommended, and set at 1 × 10−5 (see Supplementary Fig. 3a for sensitivity analysis of the IFNAR2 locus in naive CD8+ T cells). An eGene was said to have evidence of colocalization when the posterior probability of colocalization of a GWAS variant and an eQTL linked to the eGene (PP4) was greater than 0.5 and PP4/PP3 ratio ≥5[15,18-21]. As the COLOC framework assumes a single causal variant per colocalized region, we listed the corresponding colocalized variant in Supplementary Data 3. Finally, we selected only those variants (and corresponding eGenes) which are either eQTLs or exhibit strong LD (r2 > 0.80) with an eQTL. LD was computed using PLINK (v1.90b3w).

TWAS analysis

We performed a transcriptome-wide association study (TWAS) using DICE eQTL datasets from 13 immune cell types and two cell types in activated conditions. We used the PrediXcan package[17] with recommended minor modifications[52] to first generate prediction models of gene expression in immune cell types using the DICE eQTL database. We utilized genotype data and normalized gene expression data (transcript per million (TPM)) to perform prediction model training, as described[17]. Briefly, we limited our analysis to genes annotated as protein-coding, lncRNA, or miRNA. The first two principal components of the genotyping data were used as covariates for the analysis. For each gene-cell-type pair, we used the Elastic Net algorithm to train the prediction models. We used default settings in PrediXcan: 0.5 as mixing parameter and use genetic variants in a 1 Mb region upstream of the gene start site and 1 Mb downstream of the gene end site, and then performed tenfold cross-validation. Gene prediction models with a cross-validated correlation value >0.1 and a cross-validated prediction performance P value <0.05 were used for downstream analysis. We then performed transcriptome-wide association applying the MetaXcan framework[17]. For single-tissue TWAS, the S-PrediXcan framework[17] was utilized for performing a total of 30,997 gene-cell-type pairs (15 immune cell types/conditions) using our prediction models and GWAS summary statistics for all reported COVID-19 phenotypes. We used a Bonferroni corrected P value threshold (P < 0.05/number of gene-cell-type pairs tested (30,997) = P < 1.613 × 10−6) to determine significant associations between genes located near significant GWAS variants (<1 Mb) and COVID-19 phenotypes in each immune cell type. To minimize multiple testing burdens, we also applied the S-MulTiXcan framework[16], which integrates transcriptome prediction models across all cell types by considering correlation across tissues. S-MulTiXcan was performed using cross-cell-type SNP covariance, transcriptome prediction models and GWAS summary statistics for all reported COVID-19 phenotypes. The cross-cell-type SNP covariance was computed using all variants for every gene across different cell types. To identify significant associations between genes located near significant GWAS variants (<1 Mb) and COVID-19 phenotypes, we used a Bonferroni corrected P value threshold (P < 0.05/number of genes in at least one prediction model (10,395) = P < 4.81 × 10−6).

Omni-ATAC-seq

Omni-ATAC-seq for immune cell types from two DICE donors in technical duplicates was performed as described previously[53]. Following the protocol and gating strategy previously reported[10], immune cells were enriched from peripheral blood mononuclear cells (PBMC) and sorted by FACS. For each technical replicate, 50,000 sorted cells were pelleted and washed once in phosphate-buffered saline (PBS). Nuclei were isolated with lysis buffer and washed with wash buffer as described[53]. The cells were then resuspended in 50 μl of transposition mixture and incubated at 37 °C for 30 min. After transposition DNA was purified using “DNA Clean & concentrator” kit (Zymo Research). Before library amplification, DNA was pre-amplified for five cycles to determine the required cycles of amplification. PCR amplification of DNA was performed and purified libraries were size-selected to 50–600 bp using AMPure XP beads (Beckman Coulter Life Sciences) according to the manufacturer’s protocol and subjected to 2 × 100 bp paired-end sequencing on NovaSeq6000 (Illumina), see Supplementary Data 8a for details of sequencing libraries.

ATAC-seq data analysis

For analysis of ATAC-seq data, we utilized our custom ATAC-seq data processing pipeline ATACproc (https://github.com/ay-lab/ATACProc). Briefly, single-end ATAC-seq reads were aligned to hg19 reference genome using Bowtie2 (version 2.3.3.1)[54,55], with parameters -k 4–mm –threads 8 –X 2000. We excluded the reads corresponding to the mitochondrial genome and chromosome Y. Uniquely mapped reads with mapping quality ≥ 30 were retained using SAMtools (version 1.6)[56]. Duplicate reads were discarded by Picard tool’s MarkDuplicates routine (https://broadinstitute.github.io/picard). To account for the 9 bp distance between two adapters inserted by the Tn5 transposase[57], we then shifted all the reads aligned to the positive (+) strand by +4 bp, and the reads aligned to the negative (−) strand by −5 bp, using Deeptools alignmentSieve routine[58]. We also discarded reads overlapping with the blacklisted regions (provided in https://github.com/Boyle-Lab/Blacklist/tree/master/lists). Coverage tracks were normalized by scaling factor, reads per kilobase per million mapped reads (RPKM), using the “BamCoverage” routine from deepTools[58] using the arguments “-bs 10—effectiveGenomeSize 2864785220—normalizeUsing RPKM -e 200”. MACS2 (version 2.1.0)[59] was used for peak calling, with parameters: “-g hs –q 0.05—nomodel—nolambda—keep-dup all—call-summits—shift -100—extsize 200”. WashU Epigenome Browser was used to display the tracks.

Enrichment of COVID-19-risk variants in chromatin accessibility sites

We utilized GARFIELD (v2) to investigate the enrichment patterns of COVID-19-risk variants at chromatin accessibility sites, identified by ATAC-seq analysis of the 13 DICE cell types and 2 activation conditions, and pre-defined “peaks” from ENCODE, GENCODE, and Roadmap Epigenomics project (excluding all fetal tissues; n = 224 in total)[13]. In brief, GARFIELD tool evaluates enrichment using a logistic regression model that accounts for allele frequency, distance to the TSS of the nearest gene, and the number of LD proxies (r2 ≥ 0.80; correlation based on the UK10K dataset provided by the software) to extract a set of independent variants and annotates those to a known regulatory region. Enrichment odds ratios (OR) were calculated at various GWAS P value thresholds (T; data retrieved from GWAS meta-analysis B2_ALL_leave_23andme), and significant enrichment patterns were identified using a Bonferroni corrected P value threshold (P < 9.8 × 10−5).

Fine-mapping of COVID-19-risk variants

We employed the FINEMAP package[34,35] with default settings to perform statistical fine-mapping of the COVID-19-risk variants and their LD SNPs. Summary statistics for individual genetic variants such as reference and alternate alleles, MAF, P value, and beta were obtained from the COVID-19 Host Genetics Initiative (association P value <5 × 10−8; data retrieved from each GWAS meta-analysis). In brief, for each GWAS locus, we defined a fine-mapping region as a 3 Mb window around a significant variant (P value <5 × 10−8) and merged overlapping regions (as suggested in https://github.com/FINNGEN/finemapping-pipeline). The individual GWAS meta-analyses were pre-processed into separate files per region, and fine-mapping was applied on the individual files using the package LDstore[60] to compute the LD statistics. FINEMAP was employed by allowing a maximum of ten causal SNPs (—n-causal-snps 10) and executed both stepwise conditioning (—cond) and shotgun stochastic search (—sss). A COVID-19-risk variant was defined as a fine-mapped variant if it overlapped with fine-mapping outputs from either stepwise conditioning or shotgun stochastic search approaches.

H3K27ac ChIP-seq and HiChIP for non-classical monocytes

ChIP-seq for H3K27ac modification for non-classical monocytes from 6 DICE subjects were performed as described previously[11]. Briefly, 500,000 FACS-sorted cells were crosslinked with 1% formaldehyde and flash-frozen in liquid nitrogen. Sheared chromatin from each sample was then immunoprecipitated with a polyclonal anti-H3K27ac antibody (C15410196; Diagenode) by use of an automated ancillary liquid handler SX-8G IP-Star from Diagenode. Immunoprecipitated chromatin was captured, washed, Illumina library adaptors integrated by transposase-based method, and library prepared by PCR amplification. Libraries were sequenced on an Illumina HiSeq2500 sequencer to obtain 50-bp single-end reads. ChIP-seq reads were analyzed as described previously[11]. Briefly, reads were aligned using Bowtie2 to hg19 reference genome. De-duplicated aligned reads were merged using SAMtools (http://samtools.sourceforge.net/) for all donors, to produce aggregate ChIP-seq reads. MACS2 was used for peak calling. WashU Epigenome Browser was used to display the tracks. H3K27ac HiChIP for non-classical monocytes from 6 DICE subjects were performed as described previously with some modifications[11]. Briefly, 1 M FACS-sorted cells were crosslinked with 1% formaldehyde and flash-frozen in liquid nitrogen. The nuclear fraction was isolated from fixed cells, the chromatin was digested in intact nuclei using 100 U of the 4-base cutter MboI (New England Biolabs), and the restricted ends were re-ligated. Pelleted nuclei were dissolved in 70 μl nuclear lysis buffer (50 mM Tris-HCl, pH 7.5, 10 mM EDTA, and 0.5% SDS) and sonicated using a Bioruptor for 6 cycles with 16 sec ON and 32 sec OFF. Sonicated chromatin was diluted 10 times in ChIP Dilution Buffer (50 mM Tris-HCl, pH 8.0, 167 mM NaCl, 1.1 mM EDTA, 0.55 mM EGTA, 0.11% Na-deoxycholate, 1.1% Triton X-100, 0.05% SDS, and 1X protease inhibitors) and immunoprecipitated overnight at 4 °C by incubation with 1.0 μl of H3K27ac antibody (C15410196; Diagenode), pre-coated on 15 μl protein A coated magnetic beads (Thermo Fisher Scientific). Immunocomplexes were captured, washed, and resuspended in 100 μl of elution buffer (50 mM NaHCO3 and 1% SDS) as described[11]. After reverse cross-linking at 65 °C overnight and treatment with proteinase K (Thermo Fisher Scientific), DNA was purified using affinity columns (Zymo Research) according to the manufacturer’s protocol. After adapter ligation, the biotinylated DNA was captured using Streptavidin C-1 beads according to the manufacturer’s protocol and resuspended in 20 μl of DNA elution buffer (10 mM Tris-HCl). PCR amplification of DNA was performed and purified HiChIP libraries were size selected to 300–800 bp using AMPure XP beads (Beckman Coulter Life Sciences) according to the manufacturer’s protocol and subjected to 2 × 150 bp paired-end sequencing on NovaSeq6000 (Illumina), see Supplementary Data 8b for details of sequencing libraries.

Analysis of HiChIP data

HiChIP data was analyzed as described previously[11]. Briefly, we applied the HiC-Pro pipeline[61] and mapped each end independently to hg19 reference genome, using the aligner Bowtie2. Aligned reads were then paired, and only paired reads involving two different MboI restriction sites were retained. Valid read pairs of individual samples within the distance range 10 kb–3 Mb were merged and 70 M valid pairs were randomly selected to create one aggregate HiChIP contact map. FitHiChIP[62] was then applied as described previously[11] to call statistically significant loops. A 5 kb fixed-sized bin was used to attribute a bin as peak-bin if that bin overlaps with a ChIP-seq or HiChIP-inferred peak in the reference peaks file. FitHiChIP applies fixed-size binning (here 5 kb) on the input set of valid HiChIP reads and attributes a bin as peak-bin if that bin overlaps with a ChIP-seq or HiChIP-inferred peak in the reference peaks file, subject to 1 bp minimum overlap without any slack. Otherwise, the bin is labeled as a non-peak-bin. The background (set of locus pairs used to infer the null model) as well as the foreground (i.e., set of locus pairs that were assigned a significance estimate) of FitHiChIP can be either peak-to-peak (i.e., interactions between two peak bins) or peak-to-all (i.e., interactions involving peak bins in at least one end). The default mode of FitHiChIP uses peak-to-all pairs for the foreground, which is the setting employed in this study. The binomial distribution is employed on the generated contact probabilities to estimate the P values, which are then corrected for multiple testing. Interactions with an FDR < 0.01 are considered significant and reported as loop calls. For the HiChIP samples reported in this study, we executed FitHiChIP using both loose and stringent background models but results reported in this study were from the stringent (S) background model of FitHiChIP[62].

Analysis to identify transcription factor motifs perturbed by COVID-19-risk-associated variants

COVID-19-risk variants were prioritized as potentially functional based on their overlap with cis-regulatory regions that interacted with target gene promoters (pieQTL) as described earlier[11], and the transcription factor motifs perturbed by these COVID-19-risk variants were obtained from the HaploReg v4.1 database (https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php). To identify transcription factors that bind to intergenic cis-regulatory region interacting with OAS1 promoter, we examined the ENCODE Transcription Factor Binding tracks containing 338 transcription factor ChIP-seq peaks in 130 cell types, and extracted RXRα ChIP-seq data from liver tissue and liver cell lines[36]. To determine GATA3 binding near the OAS2 gene promoter we utilized the GATA3 ChIP-seq data from human thymocytes[39].

Statistical analysis and data display

The number of subjects, samples, and replicates analyzed, and the statistical test performed are indicated in the figure legends. GraphPad Prism 9.1.0 software was used for generating graphs and performing statistical significance tests. ATAC-seq peaks, ChIP-seq peaks, and HiChIP interactions were visualized using WashU Epigenome Browser.
  54 in total

1.  Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression.

Authors:  Benjamin J Schmiedel; Divya Singh; Ariel Madrigal; Alan G Valdovino-Gonzalez; Brandie M White; Jose Zapardiel-Gonzalo; Brendan Ha; Gokmen Altay; Jason A Greenbaum; Graham McVicker; Grégory Seumois; Anjana Rao; Mitchell Kronenberg; Bjoern Peters; Pandurangan Vijayanand
Journal:  Cell       Date:  2018-11-15       Impact factor: 41.582

2.  GARFIELD classifies disease-relevant genomic features through integration of functional annotations with association signals.

Authors:  Valentina Iotchkova; Graham R S Ritchie; Matthias Geihs; Sandro Morganella; Josine L Min; Klaudia Walter; Nicholas John Timpson; Ian Dunham; Ewan Birney; Nicole Soranzo
Journal:  Nat Genet       Date:  2019-01-28       Impact factor: 38.330

3.  Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity.

Authors:  Janie F Shelton; Anjali J Shastri; Chelsea Ye; Catherine H Weldon; Teresa Filshtein-Sonmez; Daniella Coker; Antony Symons; Jorge Esparza-Gordillo; Stella Aslibekyan; Adam Auton
Journal:  Nat Genet       Date:  2021-04-22       Impact factor: 38.330

4.  Promoter-interacting expression quantitative trait loci are enriched for functional genetic variants.

Authors:  Vivek Chandra; Sourya Bhattacharyya; Benjamin J Schmiedel; Ariel Madrigal; Cristian Gonzalez-Colin; Stephanie Fotsing; Austin Crinklaw; Gregory Seumois; Pejman Mohammadi; Mitchell Kronenberg; Bjoern Peters; Ferhat Ay; Pandurangan Vijayanand
Journal:  Nat Genet       Date:  2020-12-21       Impact factor: 41.307

5.  Genetic mechanisms of critical illness in COVID-19.

Authors:  Erola Pairo-Castineira; Sara Clohisey; Lucija Klaric; Andrew D Bretherick; Konrad Rawlik; Dorota Pasko; Susan Walker; Nick Parkinson; Max Head Fourman; Clark D Russell; James Furniss; Anne Richmond; Elvina Gountouna; Nicola Wrobel; David Harrison; Bo Wang; Yang Wu; Alison Meynert; Fiona Griffiths; Wilna Oosthuyzen; Athanasios Kousathanas; Loukas Moutsianas; Zhijian Yang; Ranran Zhai; Chenqing Zheng; Graeme Grimes; Rupert Beale; Jonathan Millar; Barbara Shih; Sean Keating; Marie Zechner; Chris Haley; David J Porteous; Caroline Hayward; Jian Yang; Julian Knight; Charlotte Summers; Manu Shankar-Hari; Paul Klenerman; Lance Turtle; Antonia Ho; Shona C Moore; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Danny McAuley; Hugh Montgomery; Timothy Walsh; Alexandre C Pereira; Alessandra Renieri; Xia Shen; Chris P Ponting; Angie Fawkes; Albert Tenesa; Mark Caulfield; Richard Scott; Kathy Rowan; Lee Murphy; Peter J M Openshaw; Malcolm G Semple; Andrew Law; Veronique Vitart; James F Wilson; J Kenneth Baillie
Journal:  Nature       Date:  2020-12-11       Impact factor: 69.504

6.  Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses.

Authors:  Chris Wallace
Journal:  PLoS Genet       Date:  2020-04-20       Impact factor: 5.917

Review 7.  Immunology of COVID-19: Current State of the Science.

Authors:  Nicolas Vabret; Graham J Britton; Conor Gruber; Samarth Hegde; Joel Kim; Maria Kuksin; Rachel Levantovsky; Louise Malle; Alvaro Moreira; Matthew D Park; Luisanna Pia; Emma Risson; Miriam Saffern; Bérengère Salomé; Myvizhi Esai Selvan; Matthew P Spindler; Jessica Tan; Verena van der Heide; Jill K Gregory; Konstantina Alexandropoulos; Nina Bhardwaj; Brian D Brown; Benjamin Greenbaum; Zeynep H Gümüş; Dirk Homann; Amir Horowitz; Alice O Kamphorst; Maria A Curotto de Lafaille; Saurabh Mehandru; Miriam Merad; Robert M Samstein
Journal:  Immunity       Date:  2020-05-06       Impact factor: 31.745

8.  Exploiting the GTEx resources to decipher the mechanisms at GWAS loci.

Authors:  Alvaro N Barbeira; Rodrigo Bonazzola; Eric R Gamazon; Yanyu Liang; YoSon Park; Sarah Kim-Hellmuth; Gao Wang; Zhuoxun Jiang; Dan Zhou; Farhad Hormozdiari; Boxiang Liu; Abhiram Rao; Andrew R Hamel; Milton D Pividori; François Aguet; Lisa Bastarache; Daniel M Jordan; Marie Verbanck; Ron Do; Matthew Stephens; Kristin Ardlie; Mark McCarthy; Stephen B Montgomery; Ayellet V Segrè; Christopher D Brown; Tuuli Lappalainen; Xiaoquan Wen; Hae Kyung Im
Journal:  Genome Biol       Date:  2021-01-26       Impact factor: 17.906

9.  Bayesian test for colocalisation between pairs of genetic association studies using summary statistics.

Authors:  Claudia Giambartolomei; Damjan Vukcevic; Eric E Schadt; Lude Franke; Aroon D Hingorani; Chris Wallace; Vincent Plagnol
Journal:  PLoS Genet       Date:  2014-05-15       Impact factor: 5.917

10.  Integrating predicted transcriptome from multiple tissues improves association detection.

Authors:  Alvaro N Barbeira; Milton Pividori; Jiamao Zheng; Heather E Wheeler; Dan L Nicolae; Hae Kyung Im
Journal:  PLoS Genet       Date:  2019-01-22       Impact factor: 5.917

View more
  9 in total

Review 1.  p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics).

Authors:  Daniela Milani; Lorenzo Caruso; Enrico Zauli; Adi Mohammed Al Owaifeer; Paola Secchiero; Giorgio Zauli; Donato Gemmati; Veronica Tisato
Journal:  Front Pharmacol       Date:  2022-05-27       Impact factor: 5.988

Review 2.  Insights into Cardiovascular Defects and Cardiac Epigenome in the Context of COVID-19.

Authors:  Shreya Sarkar; Rwik Sen
Journal:  Epigenomes       Date:  2022-04-21

Review 3.  Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm.

Authors:  Abdullahi Rabiu Abubakar; Rahnuma Ahmad; Adekunle Babajide Rowaiye; Sayeeda Rahman; Katia Iskandar; Siddhartha Dutta; Angus Nnamdi Oli; Sameer Dhingra; Maryam Abba Tor; Ayukafangha Etando; Santosh Kumar; Mohammed Irfan; Marshall Gowere; Kona Chowdhury; Farhana Akter; Dilshad Jahan; Natalie Schellack; Mainul Haque
Journal:  Life (Basel)       Date:  2022-03-25

4.  ANANASTRA: annotation and enrichment analysis of allele-specific transcription factor binding at SNPs.

Authors:  Alexandr Boytsov; Sergey Abramov; Ariuna Z Aiusheeva; Alexandra M Kasianova; Eugene Baulin; Ivan A Kuznetsov; Yurii S Aulchenko; Semyon Kolmykov; Ivan Yevshin; Fedor Kolpakov; Ilya E Vorontsov; Vsevolod J Makeev; Ivan V Kulakovskiy
Journal:  Nucleic Acids Res       Date:  2022-04-21       Impact factor: 19.160

5.  SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues.

Authors:  Matteo D'Antonio; Jennifer P Nguyen; Timothy D Arthur; Hiroko Matsui; Agnieszka D'Antonio-Chronowska; Kelly A Frazer
Journal:  Cell Rep       Date:  2021-11-03       Impact factor: 9.995

6.  A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene.

Authors:  Naciye Magusali; Andrew C Graham; Thomas M Piers; Pantila Panichnantakul; Umran Yaman; Maryam Shoai; Regina H Reynolds; Juan A Botia; Keeley J Brookes; Tamar Guetta-Baranes; Eftychia Bellou; Sevinc Bayram; Dimitra Sokolova; Mina Ryten; Carlo Sala Frigerio; Valentina Escott-Price; Kevin Morgan; Jennifer M Pocock; John Hardy; Dervis A Salih
Journal:  Brain       Date:  2021-12-31       Impact factor: 15.255

7.  The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force.

Authors:  Satoru Miyano; Seishi Ogawa; Takanori Kanai; Koichi Fukunaga; Yukinori Okada; Qingbo S Wang; Ryuya Edahiro; Ho Namkoong; Takanori Hasegawa; Yuya Shirai; Kyuto Sonehara; Hiromu Tanaka; Ho Lee; Ryunosuke Saiki; Takayoshi Hyugaji; Eigo Shimizu; Kotoe Katayama; Masahiro Kanai; Tatsuhiko Naito; Noah Sasa; Kenichi Yamamoto; Yasuhiro Kato; Takayoshi Morita; Kazuhisa Takahashi; Norihiro Harada; Toshio Naito; Makoto Hiki; Yasushi Matsushita; Haruhi Takagi; Masako Ichikawa; Ai Nakamura; Sonoko Harada; Yuuki Sandhu; Hiroki Kabata; Katsunori Masaki; Hirofumi Kamata; Shinnosuke Ikemura; Shotaro Chubachi; Satoshi Okamori; Hideki Terai; Atsuho Morita; Takanori Asakura; Junichi Sasaki; Hiroshi Morisaki; Yoshifumi Uwamino; Kosaku Nanki; Sho Uchida; Shunsuke Uno; Tomoyasu Nishimura; Takashri Ishiguro; Taisuke Isono; Shun Shibata; Yuma Matsui; Chiaki Hosoda; Kenji Takano; Takashi Nishida; Yoichi Kobayashi; Yotaro Takaku; Noboru Takayanagi; Soichiro Ueda; Ai Tada; Masayoshi Miyawaki; Masaomi Yamamoto; Eriko Yoshida; Reina Hayashi; Tomoki Nagasaka; Sawako Arai; Yutaro Kaneko; Kana Sasaki; Etsuko Tagaya; Masatoshi Kawana; Ken Arimura; Kunihiko Takahashi; Tatsuhiko Anzai; Satoshi Ito; Akifumi Endo; Yuji Uchimura; Yasunari Miyazaki; Takayuki Honda; Tomoya Tateishi; Shuji Tohda; Naoya Ichimura; Kazunari Sonobe; Chihiro Tani Sassa; Jun Nakajima; Yasushi Nakano; Yukiko Nakajima; Ryusuke Anan; Ryosuke Arai; Yuko Kurihara; Yuko Harada; Kazumi Nishio; Tetsuya Ueda; Masanori Azuma; Ryuichi Saito; Toshikatsu Sado; Yoshimune Miyazaki; Ryuichi Sato; Yuki Haruta; Tadao Nagasaki; Yoshinori Yasui; Yoshinori Hasegawa; Yoshikazu Mutoh; Tomoki Kimura; Tomonori Sato; Reoto Takei; Satoshi Hagimoto; Yoichiro Noguchi; Yasuhiko Yamano; Hajime Sasano; Sho Ota; Yasushi Nakamori; Kazuhisa Yoshiya; Fukuki Saito; Tomoyuki Yoshihara; Daiki Wada; Hiromu Iwamura; Syuji Kanayama; Shuhei Maruyama; Takashi Yoshiyama; Ken Ohta; Hiroyuki Kokuto; Hideo Ogata; Yoshiaki Tanaka; Kenichi Arakawa; Masafumi Shimoda; Takeshi Osawa; Hiroki Tateno; Isano Hase; Shuichi Yoshida; Shoji Suzuki; Miki Kawada; Hirohisa Horinouchi; Fumitake Saito; Keiko Mitamura; Masao Hagihara; Junichi Ochi; Tomoyuki Uchida; Rie Baba; Daisuke Arai; Takayuki Ogura; Hidenori Takahashi; Shigehiro Hagiwara; Genta Nagao; Shunichiro Konishi; Ichiro Nakachi; Koji Murakami; Mitsuhiro Yamada; Hisatoshi Sugiura; Hirohito Sano; Shuichiro Matsumoto; Nozomu Kimura; Yoshinao Ono; Hiroaki Baba; Yusuke Suzuki; Sohei Nakayama; Keita Masuzawa; Shinichi Namba; Takayuki Shiroyama; Yoshimi Noda; Takayuki Niitsu; Yuichi Adachi; Takatoshi Enomoto; Saori Amiya; Reina Hara; Yuta Yamaguchi; Teruaki Murakami; Tomoki Kuge; Kinnosuke Matsumoto; Yuji Yamamoto; Makoto Yamamoto; Midori Yoneda; Kazunori Tomono; Kazuto Kato; Haruhiko Hirata; Yoshito Takeda; Hidefumi Koh; Tadashi Manabe; Yohei Funatsu; Fumimaro Ito; Takahiro Fukui; Keisuke Shinozuka; Sumiko Kohashi; Masatoshi Miyazaki; Tomohisa Shoko; Mitsuaki Kojima; Tomohiro Adachi; Motonao Ishikawa; Kenichiro Takahashi; Takashi Inoue; Toshiyuki Hirano; Keigo Kobayashi; Hatsuyo Takaoka; Kazuyoshi Watanabe; Naoki Miyazawa; Yasuhiro Kimura; Reiko Sado; Hideyasu Sugimoto; Akane Kamiya; Naota Kuwahara; Akiko Fujiwara; Tomohiro Matsunaga; Yoko Sato; Takenori Okada; Yoshihiro Hirai; Hidetoshi Kawashima; Atsuya Narita; Kazuki Niwa; Yoshiyuki Sekikawa; Koichi Nishi; Masaru Nishitsuji; Mayuko Tani; Junya Suzuki; Hiroki Nakatsumi; Takashi Ogura; Hideya Kitamura; Eri Hagiwara; Kota Murohashi; Hiroko Okabayashi; Takao Mochimaru; Shigenari Nukaga; Ryosuke Satomi; Yoshitaka Oyamada; Nobuaki Mori; Tomoya Baba; Yasutaka Fukui; Mitsuru Odate; Shuko Mashimo; Yasushi Makino; Kazuma Yagi; Mizuha Hashiguchi; Junko Kagyo; Tetsuya Shiomi; Satoshi Fuke; Hiroshi Saito; Tomoya Tsuchida; Shigeki Fujitani; Mumon Takita; Daiki Morikawa; Toru Yoshida; Takehiro Izumo; Minoru Inomata; Naoyuki Kuse; Nobuyasu Awano; Mari Tone; Akihiro Ito; Yoshihiko Nakamura; Kota Hoshino; Junichi Maruyama; Hiroyasu Ishikura; Tohru Takata; Toshio Odani; Masaru Amishima; Takeshi Hattori; Yasuo Shichinohe; Takashi Kagaya; Toshiyuki Kita; Kazuhide Ohta; Satoru Sakagami; Kiyoshi Koshida; Kentaro Hayashi; Tetsuo Shimizu; Yutaka Kozu; Hisato Hiranuma; Yasuhiro Gon; Namiki Izumi; Kaoru Nagata; Ken Ueda; Reiko Taki; Satoko Hanada; Kodai Kawamura; Kazuya Ichikado; Kenta Nishiyama; Hiroyuki Muranaka; Kazunori Nakamura; Naozumi Hashimoto; Keiko Wakahara; Sakamoto Koji; Norihito Omote; Akira Ando; Nobuhiro Kodama; Yasunari Kaneyama; Shunsuke Maeda; Takashige Kuraki; Takemasa Matsumoto; Koutaro Yokote; Taka-Aki Nakada; Ryuzo Abe; Taku Oshima; Tadanaga Shimada; Masahiro Harada; Takeshi Takahashi; Hiroshi Ono; Toshihiro Sakurai; Takayuki Shibusawa; Yoshifumi Kimizuka; Akihiko Kawana; Tomoya Sano; Chie Watanabe; Ryohei Suematsu; Hisako Sageshima; Ayumi Yoshifuji; Kazuto Ito; Saeko Takahashi; Kota Ishioka; Morio Nakamura; Makoto Masuda; Aya Wakabayashi; Hiroki Watanabe; Suguru Ueda; Masanori Nishikawa; Yusuke Chihara; Mayumi Takeuchi; Keisuke Onoi; Jun Shinozuka; Atsushi Sueyoshi; Yoji Nagasaki; Masaki Okamoto; Sayoko Ishihara; Masatoshi Shimo; Yoshihisa Tokunaga; Yu Kusaka; Takehiko Ohba; Susumu Isogai; Aki Ogawa; Takuya Inoue; Satoru Fukuyama; Yoshihiro Eriguchi; Akiko Yonekawa; Keiko Kan-O; Koichiro Matsumoto; Kensuke Kanaoka; Shoichi Ihara; Kiyoshi Komuta; Yoshiaki Inoue; Shigeru Chiba; Kunihiro Yamagata; Yuji Hiramatsu; Hirayasu Kai; Koichiro Asano; Tsuyoshi Oguma; Yoko Ito; Satoru Hashimoto; Masaki Yamasaki; Yu Kasamatsu; Yuko Komase; Naoya Hida; Takahiro Tsuburai; Baku Oyama; Minoru Takada; Hidenori Kanda; Yuichiro Kitagawa; Tetsuya Fukuta; Takahito Miyake; Shozo Yoshida; Shinji Ogura; Shinji Abe; Yuta Kono; Yuki Togashi; Hiroyuki Takoi; Ryota Kikuchi; Shinichi Ogawa; Tomouki Ogata; Shoichiro Ishihara; Arihiko Kanehiro; Shinji Ozaki; Yasuko Fuchimoto; Sae Wada; Nobukazu Fujimoto; Kei Nishiyama; Mariko Terashima; Satoru Beppu; Kosuke Yoshida; Osamu Narumoto; Hideaki Nagai; Nobuharu Ooshima; Mitsuru Motegi; Akira Umeda; Kazuya Miyagawa; Hisato Shimada; Mayu Endo; Yoshiyuki Ohira; Masafumi Watanabe; Sumito Inoue; Akira Igarashi; Masamichi Sato; Hironori Sagara; Akihiko Tanaka; Shin Ohta; Tomoyuki Kimura; Yoko Shibata; Yoshinori Tanino; Takefumi Nikaido; Hiroyuki Minemura; Yuki Sato; Yuichiro Yamada; Takuya Hashino; Masato Shinoki; Hajime Iwagoe; Hiroshi Takahashi; Kazuhiko Fujii; Hiroto Kishi; Masayuki Kanai; Tomonori Imamura; Tatsuya Yamashita; Masakiyo Yatomi; Toshitaka Maeno; Shinichi Hayashi; Mai Takahashi; Mizuki Kuramochi; Isamu Kamimaki; Yoshiteru Tominaga; Tomoo Ishii; Mitsuyoshi Utsugi; Akihiro Ono; Toru Tanaka; Takeru Kashiwada; Kazue Fujita; Yoshinobu Saito; Masahiro Seike; Hiroko Watanabe; Hiroto Matsuse; Norio Kodaka; Chihiro Nakano; Takeshi Oshio; Takatomo Hirouchi; Shohei Makino; Moritoki Egi; Yosuke Omae; Yasuhito Nannya; Takafumi Ueno; Tomomi Takano; Kazuhiko Katayama; Masumi Ai; Atsushi Kumanogoh; Toshiro Sato; Naoki Hasegawa; Katsushi Tokunaga; Makoto Ishii; Ryuji Koike; Yuko Kitagawa; Akinori Kimura; Seiya Imoto
Journal:  Nat Commun       Date:  2022-08-22       Impact factor: 17.694

8.  IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19.

Authors:  Ingrid Fricke-Galindo; Alfonso Martínez-Morales; Leslie Chávez-Galán; Ranferi Ocaña-Guzmán; Ivette Buendía-Roldán; Gloria Pérez-Rubio; Rafael de Jesus Hernández-Zenteno; Abigail Verónica-Aguilar; Aimé Alarcón-Dionet; Hiram Aguilar-Duran; Ilse Adriana Gutiérrez-Pérez; Oscar Zaragoza-García; Jesús Alanis-Ponce; Angel Camarena; Brandon Bautista-Becerril; Karol J Nava-Quiroz; Mayra Mejía; Iris Paola Guzmán-Guzmán; Ramcés Falfán-Valencia
Journal:  Front Immunol       Date:  2022-07-29       Impact factor: 8.786

9.  Transcriptome-wide summary data-based Mendelian randomization analysis reveals 38 novel genes associated with severe COVID-19.

Authors:  Suhas Krishnamoorthy; Gloria H-Y Li; Ching-Lung Cheung
Journal:  J Med Virol       Date:  2022-09-20       Impact factor: 20.693

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.